Skip to main content
. 2007 May 1;61(5):853–863. doi: 10.1111/j.1742-1241.2007.01318.x

Table 2.

Comparative MICs of dalbavancin and other antimicrobials against selected Gram-positive and anaerobic organisms

MIC90 range (μg/ml)*

Organism Dalbavancin Vancomycin Linezolid Teicoplanin Quin/dalfo Daptomycin
Staphylococcus aureus (25, 40, 42) 0.06 1 ≤ 2 2 0.5 NA
 Methicillin susceptible (25, 27, 41, 43, 44, 47, 48) 0.06–0.5 1 1–4 2–4 0.25–0.5 0.5
 Methicillin resistant (25, 27, 41, 43, 44, 47, 48) 0.06–1 1–4 0.5–8 2–4 0.5 0.5
 Glycopeptide intermediate (25, 39, 41) 1–2 8 8–16 2 1 NA
Staphylococcus coagulase negative (25, 40, 42) 0.06–0.12 2 4–8 1–2 0.5 NA
 Methicillin susceptible (25, 27, 43, 44, 47, 48) 0.06–0.5 2 2–8 1–2 0.25–0.5 0.5
 Methicillin resistant (25, 27, 43, 44, 47, 48) 0.06–0.5 2–4 2–16 1–2 0.5–1 0.5
 Vancomycin non-susceptible (25) 1 8 > 32 2 0.5 NA
 Teicoplanin resistant (39, 45) 0.25 2 NA 1 1 NA
Staphylococcus epidermidis
 Methicillin susceptible (27, 41) 0.25–0.5 1–2 8 NA NA NA
 Methicillin resistant (27, 41) 0.25 2–4 16 NA NA NA
Staphylococcus haemolyticus
 Methicillin susceptible (27) 0.13 2 32 NA NA 2
 Methicillin resistant (27) 0.5 4 32 NA NA NA
Streptococcus pneumoniae (25, 40, 42, 44, 46) < 0.03–0.06 0.5 0.125 to ≤ 2 1–2 < 0.5–1 NA
 Penicillin susceptible (25, 27, 48) 0.03–0.06 0.5 0.06 1 0.5 NA
 Penicillin non-susceptible (25, 27, 38, 48) ≤ 0.016–0.03 0.5 0.06 1 0.5–1 NA
Streptococcus pyogenes (25) 0.015 0.5 0.06 1 ≤ 0.12 NA
 Erythromycin susceptible (25) 0.015 0.5 0.06 1 ≤ 0.12 NA
 Erythromycin resistant (25) 0.015 0.5 0.06 1 ≤ 0.12 NA
Viridans group streptococci (25, 40, 42, 44) 0.016–0.03 1 ≤ 2 1 0.5–1 NA
 Penicillin susceptible (25, 48) 0.03 1 0.06 1 1 NA
 Penicillin non-susceptible (25, 48) 0.03 0.5–1 0.12 1 1 NA
 Erythromycin susceptible (25) 0.03 1 0.06 1 1 NA
 Erythromycin resistant (25) 0.03 1 0.12 1 1 NA
β-Haemolytic streptococci (25, 40, 42, 44, 48) 0.015–0.06 0.5 ≤ 2 1 0.5 NA
Streptococcus agalactiae (25) 0.015 0.5 0.12 1 0.25 NA
Enterococcus spp. (40, 42) 0.12–16 2 to > 16 ≤ 2 to > 16 2 > 2 NA
 Vancomycin susceptible (44) 0.5 2 0.5 NA > 8 NA
 Vancomycin resistant (44) 32 > 16 > 16 NA > 8 NA
 vanA resistant (27, 38) 32 to > 128 > 128 > 128 NA NA NA
 vanB resistant (27) 0.12–1 128 ≤ 2 2 8 NA
Enterococcus faecalis
 Vancomycin susceptible (48) 0.06 NA 0.5 2 > 8 NA
 Vancomycin resistant (38, 48) 32 NA > 16 2 > 8 NA
Enterococcus faecium
 Vancomycin susceptible (48) 0.12 NA 0.5 2 2 NA
 Vancomycin resistant (38, 48) 32 NA > 16 2 1 NA
 Quin/dalfo resistant (38) 0.12§–8 NA NA 2 NA NA
Actinomyces spp. (28) 0.5 1 NA 1 0.25 16
Bacillus spp. (44) 0.25 1 2 NA 2 NA
Clostridium spp. (28) 0.5 2 NA 4 0.5 8
Clostridium difficile (28) 0.25 2 NA 8 4 2
Clostridium perfringens(28) 0.125 0.5 NA 2 0.5 1
Corynebacterium spp.(28, 44, 48) ≤ 0.03–0.5 0.5–1 0.5 1 0.5–1 8
Corynebacterium jeikeium (28) 0.5 0.5 NA 0.5 0.5 0.25
Lactobacillus spp. (48) > 32 > 32 NA 8 2 > 32
Listeria spp. (40) 0.06 NA NA NA NA NA
Peptostreptococcus spp. (28) 0.25 0.5 NA 2 0.5 1
Propionibacterium spp. (28) 0.5 1 NA 1 0.2 16

Permission for reprint granted by Ann Pharmocother; 2006; 40: 449–60.

*

MIC90 range based on MIC90 values reported in different studies that compared dalbavancin with at least one of the comparator agents.

Data from Ref. (27) includes other coagulase-negative staphylococci, but do not include Staphylococcus epidermidis and Staphylococcus haemolyticus.

Includes penicillin-non-susceptible, penicillin-intermediate and penicillin-resistant isolates.

§

vanA negative isolates.

vanA positive isolates. MICs, minimum inhibitory concentrations; NA, not available; quin/dalfo, quinupristin/dalfopristin; vanA, vancomycin-resistant enterococci possessing the vanA gene.